United Therapeutics authorizes up to $2 billion share repurchase program
United Therapeutics' board approved a new share buyback authorization for up to $2 billion of common stock, effective through October 21 2027. The company may repurchase shares via open‑market, privately negotiated or accelerated share repurchase transactions and can start or suspend purchases at any time. The new authorization does not reduce the amount available for an ongoing accelerated share repurchase that began in September 2026 and is scheduled to end in the fourth quarter of 2026.
Why it matters
The program gives United Therapeutics flexibility to return cash to shareholders, which could support the stock price and reduce share count. RBC lowered its price target to $697 from $708 while keeping an outperform rating, reflecting analyst view on the buyback’s impact.
Key facts
- 1The board authorized a share repurchase program of up to $2 billion of common stock. marketscreener.com
- 2The authorization is effective through October 21 2027. marketscreener.com
- 3The board approved the program on October 21 2026. tradingview.com
- 4United Therapeutics has an ongoing accelerated share repurchase transaction that began in September 2026 and is scheduled to terminate in the fourth quarter of 2026. stocktitan.net
- 5U.S. Therapeutics' stock closed at $563.49, up 1.74%, and was trading at $568.37 in pre‑market on the announcement day. rttnews.com
- 6RBC lowered its price target for United Therapeutics to $697 from $708, maintaining an outperform rating. marketscreener.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.